RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now That's right .. 5, 10, 15 , 20 top tier Big Pharma companies all seeking to make "bolt-on acquisitions" to bolster their oncology product portfoilios at a time when a patent cliff looms over their pharma businesses ..... and this all spells a " BIDDING WAR' for ONCY's multifacested IMMUNE PLATFORM MOLECULE that makes multiple various cancers more susceptable to a broad range of oncology treatements, like immune checkpoint inhibitors, CAR=T therapy, bispecfics and small molecules like CDK4,6 and PARP inhibitors, for example.
https://d1io3yog0oux5.cloudfront.net/_e587e47198829357eed068ac91a928e3/oncolyticsbiotech/db/300/2536/pdf/Oncolytics+Corporate+Presentation+August.pdf